{"log_id": 6969149419151182820, "direction": 0, "words_result_num": 42, "words_result": [{"probability": {"variance": 0, "average": 0.99962, "min": 0.999406}, "location": {"width": 106, "top": 29, "height": 27, "left": 1083}, "words": "国家食品"}, {"probability": {"variance": 0.010955, "average": 0.925464, "min": 0.777447}, "location": {"width": 74, "top": 70, "height": 31, "left": 1118}, "words": "药品扌"}, {"probability": {"variance": 0, "average": 0.99995, "min": 0.99995}, "location": {"width": 28, "top": 114, "height": 26, "left": 1132}, "words": "附"}, {"probability": {"variance": 0.026244, "average": 0.906623, "min": 0.465082}, "location": {"width": 532, "top": 153, "height": 65, "left": 196}, "words": "生过量服药,应对毒性反应进行监测并进行必要的治疗"}, {"probability": {"variance": 0.002796, "average": 0.975638, "min": 0.778396}, "location": {"width": 838, "top": 202, "height": 74, "left": 236}, "words": "如果发生药物过必须测患者是否有中的证据必要时采取标准的支持疗法。可"}, {"probability": {"variance": 0.007832, "average": 0.951072, "min": 0.576412}, "location": {"width": 884, "top": 241, "height": 76, "left": 191}, "words": "以通过血液透析消除阿德福韦,阿德福韦经体重校正后的血液透析清除率中位数为"}, {"probability": {"variance": 0.00564, "average": 0.964947, "min": 0.662198}, "location": {"width": 494, "top": 285, "height": 52, "left": 200}, "words": "4 iml/min。尚未进行腹膜透析清除阿德福韦的研究"}, {"probability": {"variance": 1e-06, "average": 0.998519, "min": 0.996744}, "location": {"width": 124, "top": 326, "height": 34, "left": 194}, "words": "【药理毒理】"}, {"probability": {"variance": 0.047553, "average": 0.774109, "min": 0.465912}, "location": {"width": 159, "top": 315, "height": 69, "left": 1000}, "words": "之诚医"}, {"probability": {"variance": 0.068828, "average": 0.824493, "min": 0.371121}, "location": {"width": 91, "top": 367, "height": 31, "left": 185}, "words": "药理用"}, {"probability": {"variance": 0, "average": 0.939173, "min": 0.939173}, "location": {"width": 36, "top": 385, "height": 35, "left": 988}, "words": "/"}, {"probability": {"variance": 0.026482, "average": 0.90243, "min": 0.417167}, "location": {"width": 833, "top": 406, "height": 74, "left": 225}, "words": "作用机制:本品阿德韦酯是一种口服抗病毒药。阿得播酯在体内代谢成阿福韦"}, {"probability": {"variance": 0.017091, "average": 0.950366, "min": 0.404917}, "location": {"width": 884, "top": 445, "height": 75, "left": 182}, "words": "阿德福韦是一种单磷酸腺苷的无环核苷类似物在细胞的作用下进一步被磷酸化为有活"}, {"probability": {"variance": 0.012883, "average": 0.948136, "min": 0.49358}, "location": {"width": 886, "top": 484, "height": 77, "left": 178}, "words": "性的代谢产物即阿德福书二磷酸盐阿德损韦二磷酸盐通过下列二种方式来抑制 HBV DNA"}, {"probability": {"variance": 0.017285, "average": 0.928018, "min": 0.411372}, "location": {"width": 887, "top": 524, "height": 76, "left": 176}, "words": "多聚酶逆转录酶)是与自然底物脱氧腺苷磷竞争是整合到病毒DNA后引起DNA"}, {"probability": {"variance": 0.038258, "average": 0.850864, "min": 0.402665}, "location": {"width": 889, "top": 565, "height": 74, "left": 174}, "words": "链延长终止阿德福韦磷酸盐对HBD的制CKT是O:1M但对人"}, {"probability": {"variance": 0.027726, "average": 0.874429, "min": 0.464015}, "location": {"width": 697, "top": 603, "height": 65, "left": 172}, "words": "类DNA多聚酶a和的抑制作用较K值分别8和97M"}, {"probability": {"variance": 0.038971, "average": 0.853564, "min": 0.392945}, "location": {"width": 846, "top": 646, "height": 74, "left": 213}, "words": "抗病毒活性:在转染B的大肝瘤细胞系中生阿德福抑制509病毒DNA复制的浓度"}, {"probability": {"variance": 0.057847, "average": 0.825172, "min": 0.40179}, "location": {"width": 196, "top": 687, "height": 34, "left": 167}, "words": "(0)为0.2~2.5M"}, {"probability": {"variance": 0.013027, "average": 0.943921, "min": 0.491928}, "location": {"width": 848, "top": 726, "height": 73, "left": 210}, "words": "耐药性:对接受阿德福韦治疗仍然可检测到血清 BV DNA的患者进行了长期耐药性"}, {"probability": {"variance": 0.018776, "average": 0.916719, "min": 0.411285}, "location": {"width": 892, "top": 764, "height": 75, "left": 165}, "words": "分析(96~144周),确定了rN36T和rA18IV变异与阿德福耐药有关。体外研究发现"}, {"probability": {"variance": 0.025041, "average": 0.918501, "min": 0.421253}, "location": {"width": 883, "top": 804, "height": 76, "left": 170}, "words": "N236T变异导致BV对阿德福韦的敏感性降低4E倍,产生这种变异的616名患者的"}, {"probability": {"variance": 0.032702, "average": 0.848071, "min": 0.363456}, "location": {"width": 889, "top": 845, "height": 73, "left": 162}, "words": "血清 hbv-dna发生反跳 A1&TV变异导致阳BV对阿福韦的格降低253倍,产生"}, {"probability": {"variance": 0.044977, "average": 0.834137, "min": 0.363397}, "location": {"width": 892, "top": 885, "height": 78, "left": 158}, "words": "这种变异的2名者发生胶跳与阿福药关的异发生048周为0%0629)"}, {"probability": {"variance": 0.03667, "average": 0.850853, "min": 0.359585}, "location": {"width": 763, "top": 927, "height": 67, "left": 160}, "words": "49~96周2%(62939714周为8%3163)3年的系计发生率为39%"}, {"probability": {"variance": 0.035536, "average": 0.831956, "min": 0.37813}, "location": {"width": 841, "top": 966, "height": 75, "left": 198}, "words": "交耐药性在 BY DNA多聚酶基因上含对拉来定标药相关交交P80MrM204"}, {"probability": {"variance": 0.032113, "average": 0.814887, "min": 0.389695}, "location": {"width": 886, "top": 1007, "height": 75, "left": 161}, "words": "tM204VTL18OMM204NV3的重组1BV交异株在体外对降能福带敏感在含"}, {"probability": {"variance": 0.024491, "average": 0.898688, "min": 0.362454}, "location": {"width": 893, "top": 1048, "height": 75, "left": 152}, "words": "拉米夫定耐药相关变异V的患中阿德福韦显科BV作用其血清 HBV DNA"}, {"probability": {"variance": 0.045791, "average": 0.828901, "min": 0.391443}, "location": {"width": 584, "top": 1090, "height": 53, "left": 151}, "words": "下降的中位数为3g找数/毫升含D多聚酶变"}, {"probability": {"variance": 0.055498, "average": 0.772696, "min": 0.403445}, "location": {"width": 245, "top": 1122, "height": 34, "left": 798}, "words": "R138EWI53Q,与"}, {"probability": {"variance": 0.013961, "average": 0.934768, "min": 0.464837}, "location": {"width": 896, "top": 1123, "height": 80, "left": 148}, "words": "乙型肝炎免疫球蛋白药相关的BV变异在体外对阿体外研究显示,表"}, {"probability": {"variance": 0.024839, "average": 0.902546, "min": 0.492021}, "location": {"width": 898, "top": 1166, "height": 74, "left": 145}, "words": "达与阿德福市耐药相关的tN236T交的B对拉米夫定的敏性降低2一3倍新与阿德福"}, {"probability": {"variance": 0.029592, "average": 0.870141, "min": 0.444043}, "location": {"width": 608, "top": 1208, "height": 55, "left": 147}, "words": "韦耐药相关的rtA8IV突变的KBV对拉来夫定的敏感性降低3倍"}, {"probability": {"variance": 2e-06, "average": 0.9978, "min": 0.996622}, "location": {"width": 93, "top": 1250, "height": 31, "left": 143}, "words": "毒理研究"}, {"probability": {"variance": 0.04206, "average": 0.886384, "min": 0.379403}, "location": {"width": 853, "top": 1290, "height": 69, "left": 184}, "words": "慢性毒性:在动物试验中,以组织学改变和尿素及服高为特征的肾小管"}, {"probability": {"variance": 0.016998, "average": 0.932674, "min": 0.507104}, "location": {"width": 697, "top": 1328, "height": 60, "left": 138}, "words": "肾病,是阿德福韦酯的主要剂限制性毒性反应,在动物试验中观察到"}, {"probability": {"variance": 0.024449, "average": 0.913342, "min": 0.543454}, "location": {"width": 451, "top": 1369, "height": 48, "left": 136}, "words": "量约为推荐的人治疗量Omg天下的10倍"}, {"probability": {"variance": 0.000629, "average": 0.986088, "min": 0.93024}, "location": {"width": 136, "top": 1362, "height": 34, "left": 900}, "words": "性发生的暴露"}, {"probability": {"variance": 0.011253, "average": 0.947548, "min": 0.478186}, "location": {"width": 857, "top": 1407, "height": 65, "left": 178}, "words": "遗传毒性:阿德福韦在加和不加代谢活化系统S9的条件对鼠伤寒法门氏菌"}, {"probability": {"variance": 0.009396, "average": 0.945481, "min": 0.670095}, "location": {"width": 899, "top": 1438, "height": 68, "left": 133}, "words": "均无致突变性阿德福韦配对中国仓肺成纤维细胞CHI体外色体在加入代谢法化系"}, {"probability": {"variance": 0.01248, "average": 0.948605, "min": 0.465386}, "location": {"width": 897, "top": 1474, "height": 66, "left": 133}, "words": "统后,无明显致染色体畸变的作用阿德福韦醋对CR小鼠微核法验结果为阴性,阿德福"}, {"probability": {"variance": 0.000842, "average": 0.984385, "min": 0.886261}, "location": {"width": 449, "top": 1511, "height": 45, "left": 132}, "words": "韦在有或无代谢活化时Ames试验结果为阴性"}], "language": -1}